• Archer commences industrial design for a clinically deployable potassium testing device
• Test work demonstrated haemolysis sensing technology integration with Archer's Biochip
• Continued work on expanding the Biochip platform by demonstrating testing of lithium levels

Archer Materials Limited has made significant progress in its Biochip technology, moving towards the development of a clinically deployable potassium testing device. The company has commenced industrial design for this device, focusing on usability, manufacturability, and regulatory submission suitability. Archer has successfully integrated Hylid Diagnostics' haemolysis sensing technology with its Biochip, detecting plasma free haemoglobin at low concentrations, which is crucial for accurate potassium readings. Additionally, Archer has expanded its Biochip platform to include lithium testing, demonstrating sensitivity and accuracy within clinically relevant levels. These advancements support Archer's preparation for a pre-submission meeting with the U.S. Food and Drug Administration.